Szemészet, 2012 (149. évfolyam, 1-4. szám)

2012-03-01 / 1. szám

Szemfenéki vénás keringési zavarok

NCT00499590?term = cobaltS.rank=2.

18. COPERNICUS Study: Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz 0, Sandbrink R, Zhu X, Beckmann К, Haller JA. Vascular Endothelial Growth Factor Trap-Eye for Makular Edema Secondary to Central Retinal Vein Occlusion: Six-Month Results of the COPERNICUS Study Phase 3. Ophthalmology 2012 May; 119 (5): 1024-32. Epub 2012 Mar 2PMID: 22440275 [PubMed - in process]

19. Coscas G, Loewenstein A, Augustin A, et al. Management of Retinal Vein Occlusion - Consensus Document. Ophthalmologies 2011; 226: 4-28.

20. Czirják L, editor. Klinikai immunológia. Budapest: Medicina Könyvkiadó; 2006. p. 160.

21. Cugati S, Wang JJ, Knudtson MD, et al. Retinal Vein Occlusion and Vascular Mortality. Ophthalmology 2007; 114: 520-524.

22. Cunha-Vaz J. Retinal vein occlusion. Editorial. Ophthalmologica 2011; 226: 3. Ophthalmologica 2011; 226: 3.

23. De Sanctis MT, Cesarone MR, Belcaro G. Treatment ofretinal vein thrombosis with pentoxifylline: a controlled, randomized trial. Angiology 2002; 53 (Suppi); S35-8.

24. Dev S, Buckley EG. Optic nerve sheath decompression for progressive central retinal vein occlusion. Ophthalmic Surg Lasers 1999; 30 (3): 181-4.

25. Di Capua M, Coppola A, Albisinni R. Cardiovascular risk factors and outcome in patients with retinal vein occlusion. J Thromb Thrombolysis 2010; 30: 16-22.

25a.Dugel PU,Blumenkranz MS, Haller JA, Williams GA, Solley WA, Kleinman DM, Naor J: A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. Ophthalmology 2012:119: 124-131.

26. Ehlers JR Fekrat S. Retinal vein occlusion. Beyond the acute event. Surv Ophthalmol 2011; 56: 281-299.

27. Elman MJ. Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. Trans Am Ophthalmol Soc 1996; 94: 471-504.

28. FAVOR trial, Fluocinolon acetonide trial: www.clinicaltrals.gov.uk, 11-3-2011.

29. Finkelstein 0. Ischemic makular edema: recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol 1992; 110: 1427-1432.

30. Friedman SM. Optociliary venous anastomosis after radial optic neurotomy for central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2003; 34: 315-7.

31. Funk M, Kriechbaum K, Prager F Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sei 2009; 50: 1025-32.

32. Galileo study: Bayer and Regeneron Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion. www.regeneron.com 2011.

33. Garcia-Arumi J, Boixadera A, Martinez-Castillo V. Chorioretinal anastomosis after radial optic neurotomy for central retinal vein occlusion. Arch Ophthalmol 2003; 121: 1385-91.

34. Glacet-Bernard A, Coscas G, Chabanel A. A randomized, doublemasked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol 1994; 118: 421-9.

35. Glacet-Bernard A, Zourdani A, Milhoub M. „ ffect of isovolemic hemodilution in central retinal vein occlusion." Graefes Arch Clin Exp Ophthalmol 2001; 239: 909-14.

36. Haller JA, Bandello fj Belfort R Jr for the OZURDEX GENEVA Study Group: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with makular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1141.

37. Haller JA, Bandello E Belfort RJ, et al. Dexamethasone intravitreal implant in patients with makular edema related to branch or central retinal vein occlusion, twelve month result. Ophthamology 2011;

117: 1134-1146.

38. Hamilton AM, Kohner EM, Rosen D. Experimental retinal branch vein occlusion in Rhesus monkeys: I. Clinical appearances. Br J Ophthalmol 1979; 63: 377-387.

39. Hayreh SS, Klugman MR, Podhajsky R Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion: a 10 year prospective study. Graefe's Arch Clin Exp Ophthalmol 1990; 228: 281-285.

40. Hayreh SS, Opremcak EM, Bruce RA. Radial optic neurotomy for central retinal vein obstruction [letter]. Retina 2002; 22: 374-7.

41. Hayreh SS, Podhajsky PA, Zimmerman B. Central and Hemicentral Retinal Vein Occlusion. Role of Anti-Platelet Aggregation Agents and Anticoagulants. Ophthalmology 2011. online availabe manuscript No 2010-1009.

42. Hayreh SS, Rojas R Podhajsky L. Ocular neovascularization with retinal vascular occlusion: III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology 1983; 90: 483-495.

43. Hayreh SS, Van Heuven WAJ, Hayreh MS. Experimental retinal vascular occlusion: I. Pathogenesis of central retinal vein occlusion. Arch Ophthalmol 1978; 96: 311: 1978.

44. Hayreh SS, Zimmerman B, McCarthy MJ. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131: 61-77.

45. Hayreh SS, Zimmerman MB, Podhajsky R Incidence of various types of retinal vein occlusion and their recurrenceand demographic characteristics. Am J Ophthalmol 1994; 117: 429-41.

46. Hayreh, S S, Klugman MR, Meena B. Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase. Graefe's Arch Clin Exp Ophthalmol 1990; 228: 201.

47. Hirota A, Mishima HK, Kiuchi Y. Incidence of retinal vein occlusion at the Glaucoma Clinic of Hiroshima University. Ophthalmologica 1997; 211: 288-91.

48. Ho AC, Gray S, Rundle A. Ranibizumab in patients with makular edema following retinal vein occlusion: 12-Month Outcomes of BRAVO and CRUISE. Invest Ophthalmol Vis Sei 51 :E-Abstract 6452. Invest Ophthalmol Vis Sei 2011; 51: E-Abstract 6452.

49. Horsley W. Bevacizumab and ranibizumab in the management of non- AMD related choroidal neovascular disease, www.netag.nhs.uk/ files/appraisal-reports/Bevacizumab% 20and%20ranibizumab% 20fornon-AMD%20CNV%20Netag%20appraisal% 20reports% 20June%202009R.pdf Ac, 2011.

50. Houtsmuller AJ, Vermeulen JA, Klompe M. The influence of ticlopidine on the natural course of retinal vein occlusion. Houtsmuller AJ, Vermeulen JA, Klompe M, et al. The influence of ticlopidine on the natural course of retinal vein occlusion. Agents Actions Suppl 1984; 15: 219-29., 1984; 15: 219-29.

51. Ilhan E Celiker U, Godekmerdan A. The antiphospholipid antibody syndrome research in patients with retinal venous occlusion. Arch Med Res 36; 372-5: 2005.

52. Ip MS, Scott IU, VanVeldhuisen PC. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with makular edema secondary to central retinal vein occlusion, SCORE study report 5. Arch Ophthalmol 2009; 127: 1101-14.

53. Janssen MC, den Heijer M, Cruysberg JR, et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A metaanalysis of thrombophilic factors. Thromb Haemost 2005; 93: 1021-6.

54. Jonas JB, Akkoyun I, Kamppeter B, et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005; 19: 65-71.

55. Keane PA, Sadda SR. Retinal vein occlusion and makular edema - critical evaluation of the clinical. Clinical Ophthalmology 2011; 5: 771-781.

56. Keyser BJ, Flaharty PM, Sergott RC. Color Doppler imaging of arterial blood flow in central retinal vein occlusion. Ophthalmology 1994;